Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review

• Published in: Curēus (Palo Alto, CA) Vol. 16; no. 9; p. e68560
• Main Authors: Abdelhady, Hala A, Oumar Abakar, Adoum, Gangavarapu, Ravindra Reddy, Mahmud, Sayed A, Manandhar, Anura, Sabir, Ghadeer, Malasevskaia, Iana
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 03-09-2024; Cureus
• Subjects: Antidiabetics; Bias; Cardiology; Citation management software; Clinical trials; Cohort analysis; Diabetes; Drug therapy; Ejection fraction; Glucose; Heart failure; Internal Medicine; Libraries; Medical Subject Headings-MeSH; Meta-analysis; Observational studies; Pathology; Sodium; Subject heading schemes; Systematic review; empagliflozin; heart failure; t2dm; dapagliflozin; canagliflozin; congestive heart failure; left ventricular dysfunction; sodium-glucose cotransporter-2 inhibitors; diabetes mellitus type 2; sglt2 inhibitors
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.68560

Type 2 diabetes mellitus (T2DM) is a major global health concern with a strong association with increased cardiovascular morbidity and mortality. The prevalence of heart failure is significantly higher in the T2DM population compared to non-diabetic individuals. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have emerged as a promising therapeutic class for managing T2DM, with potential cardioprotective effects. This systematic review aims to comprehensively evaluate the impact of SGLT-2 inhibitors on cardiovascular outcomes in adult patients with T2DM. A comprehensive electronic search was conducted across multiple databases and registries from May 8 to June 6, 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Studies published between January 2019 and June 6, 2024 that evaluated the effects of SGLT-2 inhibitors on cardiovascular outcomes in adults with T2DM were included. The risk of bias was assessed using appropriate tools based on the study design. A narrative synthesis was planned to summarize the findings. The search strategy identified 25 studies (22 randomized controlled trials, three cohort studies) for inclusion in the systematic review. Most of the included studies demonstrated a low overall risk of bias, although some observational studies had some limitations. The studies investigated the effects of various SGLT-2 inhibitors, including empagliflozin, canagliflozin, dapagliflozin, and others, on cardiovascular endpoints such as heart failure-related hospitalizations, mortality, cardiac structure and function, and biomarkers. The findings suggest that SGLT-2 inhibitors may have a beneficial impact on reducing the risk of heart failure-related hospitalizations and potentially improving other cardiovascular outcomes in patients with T2DM. This comprehensive systematic review provides valuable insights into the emerging role of SGLT-2 inhibitors in mitigating cardiovascular complications associated with T2DM. The findings have important clinical implications and may inform evidence-based guidelines and treatment strategies aimed at improving cardiovascular outcomes in this high-risk patient population.